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and Outcomes Associated With Sarcoidosis in the United States
Nirav Patel, MD; Rajat Kalra, MBChB; Rajkumar Doshi, MBBS, MPH; Harpreet Arora, MBBS; Navkaranbir S. Bajaj, MD, MPH; Garima Arora,
MD, MRCP; Pankaj Arora, MD
Background-—Recent trends of hospitalizations and in-hospital mortality are not well deﬁned in sarcoidosis. We examined
aforementioned trends and prevalence of cardiovascular manifestations and explored rates of implantable cardioverter-deﬁbrillator
implantation in hospitalizations with sarcoidosis.
Methods and Results-—Using data from the National Inpatient Sample, a retrospective population cohort from 2005 to 2014 was
studied. To identify sarcoidosis, an International Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation (ICD-9-CM)
diagnosis code was used. We excluded hospitalizations with myocardial infarction, coronary artery disease, and ischemic
cardiomyopathy. Cardiovascular manifestations were deﬁned by the presence of diagnosis codes for conduction disorders,
arrhythmias, heart failure, nonischemic cardiomyopathy, and pulmonary hypertension. A total of 609 051 sarcoidosis
hospitalizations were identiﬁed, with an age of 5514 years, 67% women, and 50% black. The number of sarcoidosis
hospitalizations increased from 2005 through 2014 (138 versus 175 per 100 000, Ptrend<0.001). We observed declining trends of
unadjusted in-hospital mortality (6.5 to 4.9 per 100 sarcoidosis hospitalizations, Ptrend<0.001). Overall 31% (n=188 438) of
sarcoidosis hospitalizations had coexistent cardiovascular manifestations of one or more type. Heart failure (16%) and
arrhythmias (15%) were the most prevalent cardiovascular manifestations. Rates of implantable cardioverter-deﬁbrillator
placement were 7.5 per 1000 sarcoidosis hospitalizations (Ptrend=0.95) during the study period. Black race was associated with
21% increased risk of in-hospital mortality (odds ratio, 1.21; 95% conﬁdence interval, 1.16–1.27 [P<0.001]).
Conclusions-—Sarcoidosis hospitalizations have increased over the past decade with a myriad of coexistent cardiovascular
manifestations. Black race is a signiﬁcant predictor of in-hospital mortality, which is declining. Further efforts are needed to
improve care in view of low implantable cardioverter-deﬁbrillator rates in sarcoidosis. ( J Am Heart Assoc. 2018;7:e007844. DOI:
10.1161/JAHA.117.007844.)
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S arcoidosis is a systemic granulomatous disease
1,2 with a
predilection towards the cardiovascular system.2 Most
patients with sarcoidosis either remain clinically silent or
present with nonspeciﬁc constitutional symptoms.3 Only 5%
of patients with sarcoidosis present with cardiovascular
manifestations attributable to cardiac sarcoidosis.4 However,
biopsy-proven cardiac sarcoidosis has been reported in up to
25% of asymptomatic sarcoidosis autopsy studies.5,6 Patients
with sarcoidosis with concomitant cardiovascular manifesta-
tions have more complications and a greater risk of sudden
death.7,8 Thus, there is considerable interest in identifying
patients with sarcoidosis with concomitant cardiovascular
manifestations.9,10
In 2006, the Japan Society of Sarcoidosis and Other
Granulomatous Disorders revised their diagnostic guidelines
for cardiac sarcoidosis by creating “histologic” and “clinical”
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groups.11,12 Rather than placing additional emphasis on
histologic diagnoses of cardiac sarcoidosis, the updated
guidelines highlighted the presence of cardiovascular mani-
festations (eg, atrioventricular block and ventricular arrhyth-
mias) to diagnose sarcoidosis with presumed cardiac
involvement.11,12 In addition, the 2014 Heart Rhythm Society
consensus statement highlighted the utilization and role of
implantable cardioverter-deﬁbrillators (ICDs) for the primary
and secondary prevention of sudden cardiac death in patients
with sarcoidosis as an important direction for future
research.10 Since these guidelines were implemented, data
reporting hospitalization trends and outcomes in sarcoidosis
are lacking.
In view of the gaps in the existing literature base, a
retrospective study was conducted to determine trends of
hospitalizations and outcomes in sarcoidosis during 2005–
2014. Furthermore, we examined rates of ICD, cardiac
resynchronization therapy (CRT), and permanent pacemaker
(PPM) placement, and factors associated with in-hospital
mortality. We also examined racial disparities in outcomes in
sarcoidosis hospitalizations in a propensity matched subgroup.
Methods
Data, Materials, and Code Disclosure Statement
The National Inpatient Sample (NIS) database is publicly
available online at the following link (URL: https://www.
distributor.hcup-us.ahrq.gov/). Additional information on the
data, analytic methods, and study materials will be made
available on request from the corresponding author to other
researchers for purposes of reproducing the results or
replicating the procedure.
Data Source
Our study records were derived from the NIS.13,14 The details
regarding the NIS data have been previously published.15 The
NIS is a subset of the Healthcare Cost and Utilization Project
sponsored by the Agency for Healthcare Research and
Quality.16 The NIS is the largest publicly available all-payer
inpatient care database in the United States, including data on
7 to 8 million discharges per year, and is a stratiﬁed 20%
sample of discharges from the United States community
hospitals, excluding rehabilitation and long-term acute-care
hospitals.17 Our study sample spans from 2005 through
2014. To represent national estimates, weights were calcu-
lated using discharge weights provided by the sponsor (ie,
Agency for Healthcare Research and Quality). The NIS
constitutes data from 44 states participating in the Health-
care Cost and Utilization Project, representing more than 95%
of the United States hospitalizations.
The study cohort was derived from a deidentiﬁed publicly
available database. Hence, the study was considered exempt
from formal review by the University of Alabama at Birming-
ham’s (Birmingham, AL) institutional review board.
Study Population
The International Classiﬁcation of Diseases, Ninth Revision,
Clinical Modiﬁcation (ICD-9-CM) was used to identify our study
population. We queried the NIS database using the ICD-9-CM
diagnostic code of 135 for sarcoidosis in the primary or
secondary diagnosis ﬁelds.9,18,19 Hospitalizations with any
present or past history of myocardial infarction, coronary
artery disease, or ischemic cardiomyopathy were excluded
using ICD-9-CM diagnostic codes to avoid inﬂuence of
ischemic heart disease on trends and outcomes (Table S1).
We examined sarcoidosis hospitalizations free of prevalent
ischemic heart disease. Cardiovascular manifestations were
deﬁned by the presence of the following disease classes in
the primary or secondary diagnosis ﬁelds: conduction disor-
ders, arrhythmias, heart failure, nonischemic cardiomyopathy,
and pulmonary hypertension (Table S2).18,20–22 The NIS
variables were used to identify demographic and baseline
Clinical Perspective
What Is New?
• Rates of hospitalizations of sarcoidosis have increased from
2005 to 2014.
• In-hospital mortality associated with sarcoidosis has
decreased over the same period.
• Heart failure and arrhythmias were the most prevalent
cardiovascular manifestations in sarcoidosis followed by
pulmonary hypertension, nonischemic cardiomyopathy, and
conduction disorder.
• Notwithstanding the increasing hospitalizations with sar-
coidosis, rates of implantable cardioverter-deﬁbrillator
implantation are low, and have not shown any upward
trend from 2005 through 2014.
• Black race was signiﬁcantly associated with in-hospital
mortality.
• In a propensity match subgroup, blacks with sarcoidosis had
higher in-hospital mortality and cardiac arrest compared
with whites.
What Are the Clinical Implications?
• Cardiovascular manifestations are prevalent in sarcoidosis
hospitalizations, and aggressive screening and risk stratiﬁ-
cation of patients with sarcoidosis for cardiovascular
manifestations could be beneﬁcial.
• Implantable cardioverter-deﬁbrillator devices may be
underutilized for prevention of sudden cardiac death in
patients with sarcoidosis.
• Racial disparities in outcomes may exist in sarcoidosis.
DOI: 10.1161/JAHA.117.007844 Journal of the American Heart Association 2
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characteristics of sarcoidosis hospitalizations. Comorbidities
used in our study were derived from Elixhauser method for
quantiﬁcation of comorbidities.14 A cardiac arrest (ICD-9-CM
diagnosis code 427.5) was identiﬁed from the disease class of
arrhythmias.23 We identiﬁed all discharges who came or
required new ICD implantation or replacement while hospi-
talized (ICD-9-CM procedure codes-37.94, 37.95, and 37.96),
CRT implantation or replacement (ICD-9-CM procedural code-
00.50, 00.51), or PPM implantation (ICD-9-CM procedural
code-37.7, 37.8) by using primary and secondary procedural
ﬁelds.
Outcomes
The primary outcomes of our study were the trends of
hospitalizations, and in-hospital mortality associated with
sarcoidosis. Trends of hospitalizations and in-hospital mortality
associated with sarcoidosis. Additional analyses performed in
sarcoidosis were: (1) trends of ICD, CRT, and PPM use;
(2) factors associated with in-hospital mortality; and (3)
propensity score–matched analyses between blacks and
whites in a subgroup of the overall sarcoidosis hospitalizations.
Statistical Analysis
Primary analyses
SAS 9.4 (SAS Institute Inc) was used to analyze the NIS
database. The initial study cohort derived from the NIS was
20% stratiﬁed. To generate nationally representative esti-
mates, discharge weights provided by the sponsor (ie, Agency
for Healthcare Research and Quality) were utilized. All
analyses were performed in the weighted study cohort to
minimize biases. Categorical data were presented as weighted
frequency in percentages. Continuous data were presented as
meanSD. Trends of sarcoidosis hospitalizations were calcu-
lated using number of sarcoidosis hospitalizations divided by
total number of hospitalizations in a given year per 100 000.
Furthermore, trends of in-hospital mortality were calculated
as total number of events per 100 sarcoidosis hospitaliza-
tions. The trend analyses were performed using Jonckheere-
Terpstra test. Rates of ICD, CRT, and PPM implantation were
calculated by number of these procedures per 1000 sar-
coidosis hospitalizations. In addition, we identiﬁed factors
associated with in-hospital mortality by using a mixed effect
logistic regression model.
Subgroup analyses
A propensity score–matched model was generated to
compare in-hospital outcomes between whites and blacks.
Hospitalizations identiﬁed from a different race other than
black or white were removed before propensity matching. A
logistic regression model was performed for age, sex, and all
baseline characteristics to calculate a propensity score for
each hospitalization. Next, we matched all hospitalizations
using a one-to-one scheme without replacement using the
nearest number matching method. The primary outcome of
incident in-hospital mortality was assessed using McNemar
test. Development of in-hospital cardiac arrest in whites and
blacks was also compared using the McNemar test. Paired t
test was used to calculate hospital stay.
Results
Trends of Sarcoidosis Hospitalizations and
In-Hospital Mortality
We identiﬁed 740 762 sarcoidosis hospitalizations from 2005
to 2014. All sarcoidosis hospitalizations with any present or
past history of myocardial infarction, coronary artery disease,
or ischemic cardiomyopathy were excluded (n=131 711). A
total of 609 051 sarcoidosis hospitalizations were included in
our ﬁnal study cohort (Figure 1). Of which 188 438
hospitalizations (31%) were coded as having cardiovascular
manifestations of one or more type.
Table 1 demonstrates baseline characteristics of sarcoi-
dosis hospitalizations. The mean age of the overall cohort with
sarcoidosis was 5514 years. However, the mean age of the
cohort with cardiovascular manifestations was higher
(5914 years) compared with the cohort without cardiovas-
cular manifestations (5313 years) (Table 1). Among the
study cohort with sarcoidosis, 67% were women and 33%
were men. The distribution of sex was similar in sarcoidosis
hospitalizations with or without cardiovascular manifesta-
tions. Sarcoidosis hospitalizations were more frequent (49%)
in blacks as compared with the other races (Table 1). Both
hospitalization groups with and without cardiovascular man-
ifestations had a preponderance of blacks (54% and 47%).
Comorbidities including diabetes mellitus, hypertension, ﬂuid
and electrolyte disorders, coagulopathy, anemia, pulmonary
circulation disorder, and renal failure were more prevalent in
sarcoidosis hospitalizations who had co-existing cardiovascu-
lar manifestations (Table 1). The Southern United States
(Table 1) reported the majority (40%) of sarcoidosis hospi-
talizations. Approximately 91% of sarcoidosis hospitalizations
occurred in urban hospitals (Table 1).
Overall, hospitalizations for sarcoidosis substantially
increased from 2005 to 2014 (Ptrend<0.001) (Figure 2). The
number of sarcoidosis hospitalizations increased from 138
to 175 per 100 000 (relative increase 26%) (Figure 2).
However, rates of in-hospital mortality of sarcoidosis signif-
icantly decreased from 2005 to 2014 (6.5 versus 4.9 per 100
sarcoidosis hospitalizations) (relative decrease 26%,
Ptrend<0.001) (Figure 2).
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Prevalence of Cardiovascular Manifestations and
Rates of ICD, CRT, and PPM Implantation
The percentage prevalence of cardiovascular disease class in
sarcoidosis is shown in Figure 3. Overall, we found 31%
(n=188 438) of sarcoidosis hospitalizations (n=609 051) had
one or more of these cardiovascular manifestations. The
overall prevalence of heart failure was 15.5%, any arrhyth-
mias 14.7%, pulmonary hypertension 8.6%, nonischemic
cardiomyopathy 6.7%, and conduction disorder 2.5% among
sarcoidosis hospitalizations (Figure 3). Rates of ICDs were
steady at 7.5 per 1000 sarcoidosis admissions during the
study period (Ptrend=0.95). We observed decreased utilization
of CRT (Ptrend=0.007), and increased placement of PPMs
(Ptrend<0.001) during the study period (Figure 4).
Factors Associated With In-Hospital Mortality
Factors associated with in-hospital mortality are shown in
Table 2. Age was an independent factor associated with in-
hospital mortality (odds ratio [OR], 1.03; 95% conﬁdence
interval [CI], 1.03–1.04 [P<0.001]). After considering white
Figure 1. Flow chart of the study design and cohort selection. Sample size presented in weighted
numbers (unweighted numbers). *Presence of the International Classiﬁcation of Diseases, Ninth Revision,
Clinical Modiﬁcation (ICD-9-CM) codes 410.1-410.9, 411.1, 411.8, 412, 414.00-414.07, and 414.8 in the
primary or secondary diagnosis ﬁelds. CRT indicates cardiac resynchronization therapy; ICD, implantable
cardioverter-deﬁbrillator; NIS, National Inpatient Sample; PPM, permanent pacemaker.
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race as a reference, black race was associated with a 21%
higher risk of in-hospital mortality (OR, 1.21; 95% CI,
1.16–1.27 [P<0.001]) among sarcoidosis (Table 2). Fluid
and electrolyte disorders, liver disease, neurological disor-
ders, coagulopathy, history of heart failure, metastatic cancer,
history of pulmonary circulation disorder, and renal failure
were all associated with a greater risk of in-hospital mortality
(Table 2). In contrast, female sex was associated with 17%
lower risk of in-hospital mortality (OR, 0.83; 95% CI, 0.80–
0.87 [P<0.001]). Chronic diseases such as diabetes mellitus,
hypertension, and anemias were associated with lower risk of
in-hospital mortality (Table 2). Assuming Northeast region as
a reference, other regions had signiﬁcantly lower risk of in-
hospital mortality among sarcoidosis (Table 2).
Propensity-Matched Analyses of in-Hospital
Outcomes Between Blacks and Whites
As black race was an independent factor associated with in-
hospital mortality in sarcoidosis, we compared in-hospital
outcomes in propensity-matched whites (n=155 665) and
blacks (n=155 665) (Table 3). Black race was associated with
higher in-hospital mortality (1.8% versus 1.5%) (OR, 1.20; 95%
CI, 1.14–1.27 [P<0.001]) and cardiac arrest (0.5% versus
0.3%) (OR, 1.67; 95% CI, 1.49–1.87 [P<0.001]) compared with
white race (Table 3). Moreover, median length of hospitaliza-
tion stay was higher in blacks compared with whites (median
4 [interquartile range, 2–6] days versus 3 [interquartile range,
2–6] days, P<0.001) (Table 3).
Discussion
Our study highlights numerous key trends in the overall
sarcoidosis population. By exploring the largest national hospi-
talization database available, we found that sarcoidosis hospi-
talizations are more frequent in urban as compared with rural
hospitals, blacks as compared with other races, and in Southern
United States as compared with other regions. We observed a
26% increase in hospitalizations of sarcoidosis from 2005 to
2014. Notwithstanding the increasing hospitalizations, we
observed a 26% reduction in the rates of in-hospital mortality
in sarcoidosis over the same time period. We found that heart
failure and arrhythmias were most prevalent cardiovascular
manifestations in sarcoidosis hospitalizations. Furthermore, we
observed a steady rate of implantation of ICDs, increasing trends
of PPM implantation, and decreasing trends of implantation of
CRT among sarcoidosis hospitalizations. Lastly, we observed
evidence of racial disparities, with blacks having higher odds of
in-hospital cardiac arrest and mortality than whites in a
propensity-matched cohort derived from the study cohort.
We noted that sarcoidosis hospitalizations are more
prevalent in blacks. It follows that the geographical variation
may be attributable to the higher concentrations of blacks in
the Southern United States.24,25 The rural-urban hospital
Table 1. Baseline Characteristics of Sarcoidosis
Hospitalizations Stratiﬁed by With and Without Cardiovascular
Manifestations
Variable Name
Overall
Sarcoidosis
(N=609 051)
With
Cardiovascular
Manifestations
(n=188 438)
Without
Cardiovascular
Manifestations
(n=420 613)
Age, y 5514 5914 5313
Sex, %
Male 32.8 33.9 32.3
Female 67.2 66.1 67.7
Race, %
White 43.9 40.5 45.4
Black 49.5 54.3 47.3
Other 6.6 5.2 7.3
Comorbidities, %
Diabetes mellitus 24.9 29.3 22.9
Hypertension 52.9 58.5 50.4
Liver disease 4.5 4.2 4.7
Fluid and
electrolyte
disorder
24.2 29.2 22
Neurological
disorder
6.8 6.6 6.9
Coagulopathy 4.6 5.7 4.1
Chronic
pulmonary
disease
29.0 35.8 25.9
Anemia 18.1 20.8 16.9
Solid tumor with
metastasis
1.4 1.3 1.4
Metastatic cancer 1.6 1.2 1.8
Pulmonary
circulation
disorders
6.3 18.9 0.6
Renal failure 12.2 19.4 9.0
Hospital region, %
Northeast 25.1 23.5 25.7
Midwest 24.1 24.9 23.8
South 40.4 40.8 40.2
West 10.4 10.8 10.3
Hospital type, %
Urban 91.3 91.8 91.0
Rural 8.7 8.2 9.0
Data are presented as meanSD or percentage.
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variations of sarcoidosis observations may be somewhat
expected given that urban hospitals are more likely to have an
advanced referral network of primary and secondary care
centers. They may also have more diagnostic resources (eg,
magnetic resonance imaging and positron emission tomogra-
phy) for the early detection of sarcoidosis.
There are several possible reasons for the hospitalization
statistics of sarcoidosis in the past decade. The publication of
2 sets of formalized guidelines10,11 during the study period
(2005–2014) offered clinicians a more organized and algo-
rithmic method for the diagnostic workup of sarcoidosis,
especially with cardiovascular involvement. The availability of
these guidelines has also been complemented with rapid and
landmark advances in myocardial imaging modalities. The
development of the guidelines and imaging techniques has
undoubtedly served to enhance the early detection of
sarcoidosis, thus increasing the incidence of this
disease.10,11,26,27
There are multiple mechanistic explanations for the mortal-
ity trends and statistics seen in our investigation. It is well
recognized that age is perhaps the most signiﬁcant role player
in the development of clinical cardiovascular disease.28,29 Thus,
it follows with sarcoidosis. Moreover, the decreasing trend
(from 2005 to 2014) of in-hospital mortality in sarcoidosis can
partly be explained by the overall increasing survival from
cardiovascular diseases especially from cardiac arrest. This is
probably attributable to a combination of enhanced public
awareness of cardiac arrest and sudden cardiac death, multiple
important process- and systems-based advances in cardiac
arrest care in health care, and the publication of at least 3 sets
of targeted consensus guidelines addressing cardiopulmonary
resuscitation and post-arrest care.30–32 Hence, patients with
longstanding sarcoidosis are now living longer, and potentially
experiencing more complications from sarcoidosis that require
admission to hospital settings.
Demographic factors such as older age,29 male sex,33 and
black race9 were associated with in-hospital mortality. Our
ﬁndings are in agreement with an informative study that
examined sarcoidosis mortality from 1988 to 2007 at a
population level using data from the National Center for Health
Statistics.34 Comorbidities such as liver diseases, ﬂuid and
electrolyte imbalance, neurological disorders, coagulopathy,
cancer, and renal failure were signiﬁcant factors associated
with in-hospital morality. Unexpectedly, we observed that
hypertension, diabetes mellitus, and anemia were associated
with reduced risk of in-hospital mortality. We believe that these
observations are likely attributable to coding errors in the
reporting of chronic comorbidities, and have been inadvertently
seen as protective in previous NIS-based investigations.35,36
Our ﬁndings also add to the existing literature on
sarcoidosis. Gerke et al19 reported a 2-fold increase in
hospitalizations among sarcoidosis using the NIS from 1998
Figure 2. Rate of hospitalizations and in-hospital mortality in sarcoidosis hospitalizations from 2005 to
2014. Figure shows estimated sarcoidosis hospitalizations per 100 000 (red square), and unadjusted in-
hospital mortality per 100 sarcoidosis hospitalizations (blue triangle) in the given year. The error bars
represent percentage errors. Trend P<0.001 by Jonckheere-Terpstra test for both.
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to 2008. By quantifying prevalence of cardiovascular mani-
festations in sarcoidosis, we added more precision on clinical
reasoning of increasing sarcoidosis hospitalizations. Our
investigation helps to reiterate some of the prior ﬁndings in
the ﬁeld and estimate the prevalence of these conditions in
the contemporary era.20
Figure 4. Implantable cardioverter-deﬁbrillator (ICD), cardiac resynchronization therapy (CRT), and
permanent pacemaker (PPM) implantations per 1000 hospitalizations of sarcoidosis from 2005 to 2014.
Trend P=0.95 for ICD implantation; trend P=0.007 for CRT implantation; and trend P<0.001 for PPM
implantation by Jonckheere-Terpstra test.
Figure 3. Prevalence of cardiovascular manifestations in sarcoidosis. Data are represented in the
percentage. Overall, 31% (n=188 438) of sarcoidosis hospitalizations (n=609 051) had cardiovascular
manifestations. Individual cardiovascular manifestation may have overlapped with the other. Prevalence of
cardiovascular manifestations in sarcoidosis was classiﬁed using the International Classiﬁcation of Diseases,
Ninth Revision, Clinical Modiﬁcation (ICD-9-CM) codes (Table S2).
DOI: 10.1161/JAHA.117.007844 Journal of the American Heart Association 7
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Our investigation also addresses important issues relating
to racial disparities in sarcoidosis. Mirsaeidi et al9 previously
reported that blacks have a mortality rate that is 12 times
higher than whites with sarcoidosis in their age-adjusted
model. Their investigation used the Centers for Disease Control
and Prevention database with evaluating death certiﬁcate (the
immediate cause of death) in patients with sarcoidosis.9 We
expand on their work by using the NIS with propensity
matching on a number of demographic and clinical variables to
help further deﬁne the increased risk of mortality in blacks with
sarcoidosis. Mirsaiedi et al also reported that incident cardiac
arrest occurred at a higher rate in blacks compared with
whites.9 This is consistent with our study ﬁndings in a much
larger sample, making it more generalizable.
The results of our investigation have important implica-
tions for clinical practice and public health. On the most
basic level, we hope to inform clinicians that the co-
occurring of cardiovascular manifestations in sarcoidosis are
devastating and could be a leading cause of death. Our
investigation also highlights that aggressive primary and
secondary prevention of comorbid cardiovascular and pul-
monary conditions is critical for patients with sarcoidosis.
Our investigation also serves as a stark reminder of the need
to aggressively pursue these preventive measures to ame-
liorate these longstanding cardiovascular racial disparities.
We hope that our investigation offers an impetus for clinical
Table 2. Factors Associated With In-Hospital Mortality in
Sarcoidosis Hospitalizations
Variable Name OR (95% CI) P Value
Age* 1.03 (1.03–1.04) <0.001
Female vs male 0.83 (0.80–0.87) <0.001
Race
White Referent
Black 1.21 (1.16–1.27) <0.001
Other 1.25 (1.19–1.32) <0.001
Comorbidities†
Diabetes mellitus 0.88 (0.84–0.92) <0.001
Hypertension 0.60 (0.58–0.63) <0.001
Liver disease 1.44 (1.34–1.54) <0.001
Fluid and electrolyte disorder 2.69 (2.59–2.79) <0.001
Neurological disorder 1.34 (1.26–1.43) <0.001
Coagulopathy 3.14 (2.98–3.31) <0.001
Chronic pulmonary disease 1.10 (1.05–1.14) <0.001
Congestive heart failure 1.98 (1.89–2.08) <0.001
Anemia 0.80 (0.77–0.84) <0.001
Solid tumor with metastasis 1.58 (1.41–2.78) <0.001
Metastatic cancer 3.76 (3.49–4.09) <0.001
Pulmonary circulation disorders 2.39 (2.27–2.52) <0.001
Renal failure 1.54 (1.46–1.61) <0.001
Hospital region
Northeast Referent
Midwest 0.79 (0.75–0.84) <0.001
South 0.92 (0.88–0.97) <0.001
West 0.91 (0.85–0.97) 0.005
Data are presented in odds ratio with 95% conﬁdence interval.
CI indicates conﬁdence interval; OR, odds ratio.
*Age is a continuous variable.
†Reference group is not present for these variables.
C statistic 0.78.
Table 3. Propensity Score Matched Cohort (1:1) of
Sarcoidosis Hospitalizations Between Blacks and Whites
Variable Name
Blacks
(n=155 665)
Whites
(n=155 665) P Value
Age, y 54.212.3 54.312.6 0.11
Sex, %
Female 75.8 75.8 0.71
Male 24.2 24.2
Comorbidities, %
Diabetes mellitus 24.2 24.2 0.71
Hypertension 52.5 52.8 0.09
Liver disease 3.1 3.2 0.32
Fluid and electrolyte
disorder
22.1 22.1 0.88
Neurological disorder 5.2 5.4 0.17
Coagulopathy 3.0 2.8 0.40
Chronic pulmonary disease 27.6 27.5 0.33
Congestive heart failure 6.6 7.0 0.22
Anemia 14.8 15 0.06
Solid tumor with metastasis 1.4 1.3 0.70
Metastatic cancer 1.6 1.7 0.15
Pulmonary circulation
disorders
3.8 3.9 0.16
Renal failure 9.3 9.4 0.28
In-hospital outcomes
In-hospital mortality 1.8 1.5 <0.001
Length of stay,
median (IQR)*
4 (2–6) 3 (2–6) <0.001
Cardiac arrest, % 0.5 0.3 <0.001
In-hospital outcomes, OR (95% CI)
In-hospital mortality 1.20 (1.14–1.27) <0.001
Cardiac arrest 1.67 (1.49–1.87) <0.001
Data are presented as meanSD or number (percentage) or percentage. CI indicates
conﬁdence interval; OR, odds ratio.
*Interquartile range (IQR) is from Q1 to Q3.
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groups to achieve the aforementioned prevention through
greater clinical collaboration by forming specialist sarcoido-
sis with cardiovascular manifestations clinics and/or spe-
cialist centers. Finally, our data again emphasize that
clinicians and investigators alike have an important respon-
sibility to proactively investigate this condition. Conse-
quently, we hope that the need and motivation for further
observational and randomized controlled trial data are
renewed through our investigation, consistent with the Heart
Rhythm Society’s visions for the future.10
Limitations
We recognize that our analysis also has limitations.
Retrospective studies have well-known limitations. However,
the use of a retrospective analysis in this investigation
affords us the opportunity to access a large group of
hospitalizations with a disease that has relatively low
incidence and prevalence rates. Large administrative
databases such as the NIS are lacking readmission status
and cause of death and are prone to coding errors. There
can be misinterpretation of procedure volumes and under-
reporting of comorbid conditions.23,35 We have identiﬁed
prevalence of cardiovascular manifestations in sarcoidosis
by presence of concurrent diagnosis codes. Although we
excluded all hospitalizations with old or present myocardial
infarction, coronary artery disease, and ischemic cardiomy-
opathy, we cannot validate that the cardiovascular manifes-
tations were caused by cardiac sarcoidosis in the absence
of histologic evidence. Also, the ICD-9-CM procedural code
37.94 is used to describe both the implantation and
replacement of ICDs. The ICD-9-CM procedural code 00.51
is used for implantation and replacement of CRT. Similarly,
ICD-9-CM procedural code 37.7 and 37.8 are used for
implantation and replacement of PPM. We may not know
whether the admission was for an ICD or CRT or PPM
implantation or replacement. Elective implantation of an
ICD, CRT, or PPM may not have been captured completely
in our investigation.
Conclusions
This NIS-based retrospective investigation shows that hospi-
talizations of sarcoidosis have increased considerably over
the past decade with declining in-hospital mortality. Further-
more, our study summarizes the prevalence of cardiovascular
manifestations, rate of device placement, and factors asso-
ciated with in-hospital mortality in sarcoidosis hospitaliza-
tions. Subgroup analyses in a propensity-matched cohort
show that blacks had a higher incidence of in-hospital
mortality and cardiac arrest compared with whites. Aggressive
screening of patients with sarcoidosis for cardiovascular
manifestations should be considered for prevention of cardiac
arrest in sarcoidosis.
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SUPPLEMENTAL MATERIAL 
 
 
 
  
Table S1. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-
9-CM) Codes Used to Exclude Sarcoidosis Hospitalizations with Ischemic Heart Diseases 
 
*Each hospitalization may have one or more diagnosis codes. 
  
Diagnosis ICD-9 CM Codes 
ST Segment Elevated Myocardial Infarction 
(n=3,455) 
410.1, 410.2, 410.3, 410.4, 410.5, 410.6, 
410.8, 410.9 
Non-ST Segment Elevated Myocardial 
Infarction (n=10,802) 
410.7 
Unstable Angina (n=8,774) 411.1, 411.8 
Old Myocardial Infarction (n=28,374) 412 
Coronary Artery Disease (n=114,086) 414.00-414.07 
Ischemic Cardiomyopathy (n=9,498) 414.8 
Table S2. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-
9-CM) Codes Included to Identify Cardiovascular Manifestations in Sarcoidosis 
 
Diagnosis ICD-9 CM Codes 
Conduction Disorder 426.0, 426.10, 426.11, 426.12, 426.13, 426.2, 
426.3, 426.4, 426.5, 426.6, 426.7, 426.8, 
426.81, 426.82, and 426.9 
Arrhythmias 427.0, 427.1, 427.2, 427.31, 427.32, 427.41, 
427.42, 427.5, 427.6, 427.8, and 427.9 
Heart Failure 428.0, 428.1, 428.2, 428.3, 428.4, and 428.9 
Pulmonary Hypertension 416.0, 416.8, and 416.9 
Cardiomyopathies 425 
 
